Compare EQPT & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQPT | APLS |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | 8206 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.2B |
| IPO Year | N/A | 2015 |
| Metric | EQPT | APLS |
|---|---|---|
| Price | $20.11 | $40.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 21 |
| Target Price | ★ $40.50 | $32.71 |
| AVG Volume (30 Days) | 1.4M | ★ 6.6M |
| Earning Date | 03-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $20.16 | N/A |
| Revenue Next Year | $24.12 | $18.21 |
| P/E Ratio | ★ N/A | $202.08 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $18.80 | $16.10 |
| 52 Week High | $35.50 | $40.48 |
| Indicator | EQPT | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 32.57 | 87.61 |
| Support Level | $19.61 | $19.38 |
| Resistance Level | $34.95 | N/A |
| Average True Range (ATR) | 1.73 | 0.54 |
| MACD | -0.05 | 2.77 |
| Stochastic Oscillator | 20.36 | 99.70 |
EquipmentShare.com Inc is a vertically integrated platform that combines proprietary technology, a connected equipment fleet, and a nationwide footprint to serve the construction industry. The company operates its business through the following reportable segments: Equipment Rental and Services Operations, comprised of recurring activity performed at full-service branch locations, such as equipment rentals and related services, and sales of parts, supplies, and maintenance services to construction contractors and others. Equipment Sales, sales of new or used equipment made at any of the branch locations and dealership sites, including equipment sales to participants in the OWN Program.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).